{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:05:25Z","timestamp":1776755125440,"version":"3.51.2"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Checkpoint-Inhibition (CPI) with PD-1- and PD-L1-inhibitors is a well-established therapy for advanced stage melanoma patients. CPI mainly acts <jats:italic>via<\/jats:italic> T-lymphocytes. However, recent literature suggests also a role for B cells modulating its efficacy and tolerability of CPI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Report<\/jats:title><jats:p>We report a 48-year-old female patient with metastatic melanoma affecting brain, lung, skin and lymph nodes. A preexisting granulomatosis with polyangiitis was treated with rituximab over five years prior to the diagnosis of melanoma, resulting in a complete depletion of B cells both in peripheral blood as well as the tumor tissue. In the absence of the mutation of the proto-oncogene b-raf, treatment with the PD-1 inhibitor nivolumab was initiated. This therapy was well tolerated and resulted in a deep partial response, which is ongoing for 14+ months. Flow cytometric analysis of peripheral blood mononuclear cells revealed 15% IL-10 producing and 14% CD24 and CD38 double positive regulatory B cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The exceptional clinical response to nivolumab monotherapy in our patient with depleted B cells sheds a new light on the relevance of B cells in the modulation of immune responses to melanoma. Obviously, B cells were not required for the efficacy of CPI in our patient. Moreover, the depletion of regulatory B cells may have improved efficacy of CPI.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.733961","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T13:02:53Z","timestamp":1633438973000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells"],"prefix":"10.3389","volume":"12","author":[{"given":"Lena Margarethe","family":"Wulfken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen Christian","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Hayajneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette Doris","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Schaper-Gerhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Flatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imke","family":"Grimmelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8","article-title":"B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary Lymphoid Structures in the Era of Cancer Immunotherapy","volume":"19","author":"Sautes-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41467-017-00452-4","article-title":"Tumor-Associated B-Cells Induce Tumor Heterogeneity and Therapy Resistance","volume":"8","author":"Somasundaram","year":"2017","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","article-title":"B Cell Repopulation Kinetics After Rituximab Treatment in ANCA-Associated Vasculitides Compared to Rheumatoid Arthritis, and Connective Tissue Diseases: A Longitudinal Observational Study on 120 Patients","volume":"19","author":"Thiel","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16651","article-title":"Deficit of Circulating CD19+ CD24hi CD38hi Regulatory B Cells in Severe Aplastic Anaemia","volume":"190","author":"Zaimoku","year":"2020","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5588","article-title":"CD19+ CD24hi CD38hi Bregs Involved in Downregulate Helper T Cells and Upregulate Regulatory T Cells in Gastric Cancer","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","first-page":"13083","DOI":"10.1038\/s41598-019-49581-4","article-title":"Increased Regulatory B Cells Are Involved in Immune Evasion in Patients With Gastric Cancer","volume":"9","author":"Murakami","year":"2019","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s40425-019-0613-1","article-title":"B Cell Depletion or Absence Does Not Impede Anti-Tumor Activity of PD-1 Inhibitors","volume":"7","author":"Damsky","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(01)00094-2","article-title":"Targeting of Lymphotoxin-Alpha to the Tumor Elicits an Efficient Immune Response Associated With Induction of Peripheral Lymphoid-Like Tissue","volume":"14","author":"Schrama","year":"2001","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.02.016","article-title":"Regulatory B1a Cells Suppress Melanoma Tumor Immunity via IL-10 Production and Inhibiting T Helper Type 1 Cytokine Production in Tumor-Infiltrating CD8+ T Cells","volume":"139","author":"Kobayashi","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e000897","DOI":"10.1136\/jitc-2020-000897","article-title":"Immune Checkpoint Inhibition Therapy for Advanced Skin Cancer in Patients With Concomitant Hematologic Malignancy: A Retrospective Multicenter Decog Study of 84 Patients","volume":"8","author":"Leiter","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3018-19","article-title":"Non-Small Cell Lung Cancer Treated by an Anti-Programmed Cell Death-1 Antibody Without a Flare-Up of Preexisting Granulomatosis With Polyangiitis","volume":"58","author":"Yamada","year":"2019","journal-title":"Intern Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.733961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T13:02:55Z","timestamp":1633438975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.733961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,5]]},"references-count":13,"alternative-id":["10.3389\/fimmu.2021.733961"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.733961","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,5]]},"article-number":"733961"}}